192 results on '"Yoshifumi Tada"'
Search Results
2. Overlapping rheumatoid meningitis with anti‐N‐methyl‐D‐aspartate receptor encephalitis: A case report
- Author
-
Toshihiro Ide, Takeru Kawanami, Yoshifumi Tada, and Makoto Eriguchi
- Subjects
anti‐N‐methyl‐D‐aspartate receptor encephalitis ,intravenous immunoglobulin ,intravenous methylprednisolone ,rheumatoid arthritis ,rheumatoid meningitis ,Medicine ,Medicine (General) ,R5-920 - Abstract
Abstract A 66‐year‐old woman in treatment for rheumatoid meningitis was found to be positive for anti‐N‐methyl‐D‐aspartate receptor (NMDAR) antibodies in the cerebrospinal fluid, and intravenous immunoglobulin improved her psychiatric symptoms. The co‐existence of NMDAR antibodies should be considered in cases of poor response to treatments or atypical symptoms in rheumatoid meningitis.
- Published
- 2023
- Full Text
- View/download PDF
3. Usefulness of Sarilumab in Patients with Rheumatoid Arthritis after Regression of Lymphoproliferative Disorders
- Author
-
Yoshifumi Tada, Akira Maeyama, Tomonobu Hagio, Mariko Sakai, Akihito Maruyama, and Takuaki Yamamoto
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Lymphoproliferative disorders (LPDs) are serious complications associated with rheumatoid arthritis (RA) treatment that mostly occur during methotrexate (MTX) treatment. Cessation of MTX may induce regression of LPDs but is often followed by a flare of RA. Here, we describe two patients with RA flares after the discontinuation of MTX due to LPDs and sarilumab was useful for the treatment of RA without a relapse of LPDs. Patient 1 was an 84-year-old woman, who developed an LPD in the pharyngeal region after 7 years of MTX treatment. Discontinuation of MTX induced regression of LPD but RA flared within 6 months. Administration of sarilumab, in addition to salazosulfapyridine and prednisolone, reduced the RA activity without LPD relapse. Patient 2 was a 76-year-old man, who developed LPD in the pharyngeal region after 5 years of MTX treatment. Discontinuation of MTX induced regression of LPD, but soon RA flared. Although treatment with tocilizumab (TCZ) was effective in controlling RA, it flared again after 2 years. TCZ was switched to sarilumab and RA was in remission. LPD did not recur during these periods.
- Published
- 2023
- Full Text
- View/download PDF
4. Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan
- Author
-
Shin-ya Kawashiri, Yushiro Endo, Ayako Nishino, Momoko Okamoto, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Remi Sumiyoshi, Tomohiro Koga, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Toshiyuki Aramaki, Yukitaka Ueki, Tamami Yoshitama, Nobutaka Eiraku, Naoki Matsuoka, Akitomo Okada, Keita Fujikawa, Hiroaki Hamada, Shuji Nagano, Yoshifumi Tada, and Atsushi Kawakami
- Subjects
Rheumatoid arthritis ,Musculoskeletal ultrasound ,Abatacept ,Dickkopf-1 ,Osteoprotegerin ,Power Doppler ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. Methods We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients’ clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. ‘Power Doppler (PD) responder’ was defined as a patient whose Δtotal PD score over 6 months was greater than the median change. Results Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23–0.91, p = 0.043) was an independent predictor of PD responder status. Conclusion Serum levels of bone biomarkers may be useful for predicting RA patients’ therapeutic responses to abatacept. Trial registration Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study Trial registration number: UMIN000012524 Date of registration: 12/9/2013 URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657
- Published
- 2021
- Full Text
- View/download PDF
5. Development of a rapid scabies immunodiagnostic assay based on transcriptomic analysis of Sarcoptes scabiei var. nyctereutis
- Author
-
Teruo Akuta, Daisuke Minegishi, Nobuhide Kido, Keitaro Imaizumi, Shinji Nakaoka, Shin-Ichiro Tachibana, Kenji Hikosaka, Fumi Hori, Masataka, Nakagawa, Chiaki Sakuma, Yuki Oouchi, Yu Nakajima, Sohei Tanaka, Tomoko Omiya, Kouki Morikaku, Minori Kawahara, Yoshifumi Tada, Hiroshi Tarui, Takafumi Ueda, Takane Kikuchi-Ueda, and Yasuo Ono
- Subjects
Medicine ,Science - Abstract
Abstract Scabies is a highly contagious skin disease caused by the mite Sarcoptes scabiei that affects many mammals. However, the sensitivity of traditional tests for scabies diagnosis in humans is less than 50%. To simplify the diagnosis of scabies, methods that are simple, sensitive, specific, and cost-effective are required. We developed an immunodiagnostic test based on S. scabiei var. nyctereutis RNA-seq data collected from Japanese raccoon dogs with sarcoptic mange. Three candidate antigens—a highly expressed hypothetical protein “QR98_0091190,” another mite allergen known as “SMIPP-Cc,” and an abundant “vitellogenin-like protein”—were evaluated by western-blot analysis. A lateral flow immunoassay, using specific antibodies against the vitellogenin-like protein, successfully detected scabies in the skin flakes of S. scabiei-infected raccoon dogs. This assay can potentially diagnose scabies more accurately in wildlife, as well as in humans.
- Published
- 2021
- Full Text
- View/download PDF
6. Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan
- Author
-
Yushiro Endo, Shin-ya Kawashiri, Shimpei Morimoto, Ayako Nishino, Momoko Okamoto, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Remi Sumiyoshi, Takashi Igawa, Tomohiro Koga, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Yukitaka Ueki, Tamami Yoshitama, Nobutaka Eiraku, Naoki Matsuoka, Akitomo Okada, Keita Fujikawa, Hiroaki Hamada, Tomomi Tsuru, Shuji Nagano, Yojiro Arinobu, Toshihiko Hidaka, Yoshifumi Tada, and Atsushi Kawakami
- Subjects
rheumatoid arthritis ,doppler ultrasonography ,tumour necrosis factor inhibitor ,non-tumour necrosis factor inhibitor ,retention ,Immunologic diseases. Allergy ,RC581-607 - Abstract
To compare therapeutic efficacy of tumour necrosis factor inhibitor (TNFi) cyclers and non-TNFi switchers in patients with rheumatoid arthritis (RA) having inadequate response to previous TNFis (TNF-IR patients) using composite measures including imaging assessment with power Doppler ultrasonography (PDUS). Patients with RA who had inadequate response to one or more previous TNFi agents with moderate or higher disease activity were enrolled. The outcomes of 56 TNF-IR patients were analysed. Patients were divided into 19 TNFi cyclers and 37 non-TNFi switchers (16 abatacept [ABT] and 21 tocilizumab [TCZ] switchers). Retention ratio at 6 months was significantly higher in non-TNFi switchers than in TNFi cyclers (p
- Published
- 2020
- Full Text
- View/download PDF
7. Immediate Effect of Baricitinib on Arthritis and Biological Disease-Modifying Antirheumatic Drug-Induced Psoriasis-Like Skin Lesions in Two Patients with Rheumatoid Arthritis
- Author
-
Yoshifumi Tada, Nobuyuki Ono, and Syuichi Koarada
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Biological disease-modifying antirheumatic drugs (bDMARDs) are very effective for treating rheumatoid arthritis (RA). However, they sometimes induce adverse events such as psoriasis-like skin lesions. We describe psoriasis-like skin lesions that developed simultaneously with an RA flare in patient 1 during treatment with abatacept and in patient 2 soon after starting certolizumab pegol. The skin lesions persisted in patient 2 despite stopping certolizumab. Baricitinib was initiated because of RA flare and resulted in immediate beneficial effects on arthritis as well as skin lesions. The RA went into remission in both patients, and the psoriasis-like skin lesions disappeared within four weeks (patient 1) and three months (patient 2).
- Published
- 2021
- Full Text
- View/download PDF
8. Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
- Author
-
Syuichi Koarada, Masahiko Tsuboi, Mitsunori Komine, Yoshinobu Nakao, Yukiko Tokuda, Yukihide Ono, Satoko Tashiro, Akihito Maruyama, Nobuyuki Ono, Akihide Ohta, and Yoshifumi Tada
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
We report four cases of successful treatment with certolizumab pegol (CZP) of rheumatoid arthritis (RA) patients with persistent inflamed residual mono- or oligosynovitis resistant to prior TNF-α inhibitors. Although the patients were in a moderate disease activity, a low activity, or a remission of RA, they sustained inflammatory mono-/oligoarthritis even after treatment with prior TNF inhibitors. They were then all treated with CZP and observed in a serial ultrasonography. In all cases, the positive power Doppler signals in the joint have disappeared promptly and all of the patients were able to retain remission in the long term. The treatment of CZP to the refractory mono-/oligoarthritis of inflammatory synovitis in RA patients has not been previously described. The cases suggest that it may be associated with the feature of CZP, possible effective penetration into the site of inflammation.
- Published
- 2015
- Full Text
- View/download PDF
9. Load-Deflection and Friction Properties of PEEK Wires as Alternative Orthodontic Wires
- Author
-
Yoshifumi Tada, Tohru Hayakawa, and Yoshiki Nakamura
- Subjects
orthodontic wire ,PEEK ,static friction ,load deflection ,three-point bending ,Technology ,Electrical engineering. Electronics. Nuclear engineering ,TK1-9971 ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Microscopy ,QH201-278.5 ,Descriptive and experimental mechanics ,QC120-168.85 - Abstract
Polyetheretherketone (PEEK) is now attracting attention as an alternative to metal alloys in the dental field. In the present study, we evaluated the load-deflection characteristics of PEEK wires in addition to their frictional properties. Three types of PEEK wires are used: two sizes of rectangular shape, 0.016 × 0.022 in2 and 0.019 × 0.025 in2 (19-25PEEK), and rounded shape, diameter 0.016 in (16PEEK). As a control, Ni-Ti orthodontic wire, diameter 0.016 in, was used. The three-point bending properties were evaluated in a modified three-point bending system for orthodontics. The static friction between the orthodontic wire and the bracket was also measured. The load-deflection curves were similar among Ni-Ti and PEEK wires, except for 16PEEK with slot-lid ligation. The bending force of 19-25PEEK wire was comparable with that of Ni-Ti wire. 19-25PEEK showed the highest load at the deflection of 1500 μm (p < 0.05) in the case of slot-lid ligation. No significant differences were seen in the permanent deformation between Ni-Ti and all three PEEK wires (p > 0.05). No significant difference was seen in static friction between all three PEEK wires and Ni-Ti wire (p > 0.05). It is suggested that 19-25PEEK will be applicable for orthodontic treatment with the use of slot-lid ligation.
- Published
- 2017
- Full Text
- View/download PDF
10. RP105-Negative B Cells in Systemic Lupus Erythematosus
- Author
-
Syuichi Koarada and Yoshifumi Tada
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Abstract
Systemic lupus erythematosus (SLE) is a multisystem disease characterized by B cells producing autoantibodies against nuclear proteins and DNA, especially anti-double-strand DNA (dsDNA) antibodies. RP105 (CD180), the toll-like receptor- (TLR-) associated molecule, is expressed on normal B cells. However, RP105-negative B cells increase in peripheral blood from patients with active SLE. RP105 may regulate B-cell activation, and RP105-negative B cells produce autoantibodies and take part in pathophysiology of SLE. It is possible that targeting RP105-negative B cells is one of the treatments of SLE. In this paper, we discuss the RP105 biology and clinical significance in SLE.
- Published
- 2012
- Full Text
- View/download PDF
11. Phenotyping of P105-Negative B Cell Subsets in Patients with Systemic Lupus Erythematosus
- Author
-
Syuichi Koarada, Yoshifumi Tada, Rie Suematsu, Sachiko Soejima, Hisako Inoue, Akihide Ohta, and Kohei Nagasawa
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Abstract
This study aimed to investigate phenotype of RP105(−) B cell subsets in patients with systemic lupus erythematosus (SLE). Flow cytometry was used for phenotyping RP105-negaive B cell subsets. Based on CD19, RP105, and CD138 expression, RP105(−) B cells consist of at least 5 subsets of late B cells, including CD19(+)RP105(int), CD19(+) RP105(−), CD19(low) RP105(−) CD138(−), CD19(low) RP105(−)CD138(int), and CD19(low) RP105(−) CD138(++) B cells. Especially, CD19(+)RP105(int) and CD19(low) RP105(−)CD138(int) B cells are significantly larger than other RP105(−) B cell subsets in SLE. By comparison of RP105(−) B cell subsets between patients with SLE and normal subjects, these subsets were detectable even in normal subjects, but the percentages of RP105(−) B cell subsets were significantly larger in SLE. The phenotypic analysis of RP105(−) B cell subsets suggests dysregulation of later B cell subsets in SLE and may provide new insights into understanding regulation of B cells in human SLE.
- Published
- 2012
- Full Text
- View/download PDF
12. Relationships between Type 1 interferon signatures and clinical features of the new-onset lupus patients in Japan.
- Author
-
Yuri Shirahama, Aki Hashimoto, Nobuyuki Ono, Yukiko Takeyama, Akihito Maruyama, Takuya Inoue, Yoshifumi Tada, and Hiroaki Niiro
- Subjects
TYPE I interferons ,LEUCOCYTES ,SYSTEMIC lupus erythematosus ,HOSPITAL admission & discharge ,DNA antibodies - Abstract
Objectives: The objective of the study is to investigate the relationships between Type 1 interferon (T1-IFN) signatures and clinical characteristics of lupus patients. Methods: We examined 49 new-onset lupus patients who were diagnosed between 1999 and 2017. The patients treated with >10 mg of prednisolone or hydroxychloroquine were excluded from this study. Serum T1-IFN signatures were revealed by a functional reporter assay and standardized by recombinant IFN-α. Patient backgrounds, clinical findings, and treatments were retrospectively extracted from their electrical medical records. Clinical data were also available, including SLE Disease Activity Index of SLE patients on admission. Results: T1-IFN signatures of lupus patients closely correlated with lupus disease activities, such as SLE Disease Activity Index-2K, white blood cell, C3 levels, and the titre of double-strand DNA antibody. We found fever and acute lupus dermatitis closely associated with T1-IFN signature. Conclusions: In lupus patients, fever and acute lupus dermatitis are good indicators of a strong T1-IFN signature. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study
- Author
-
Xianyong, Yin, Kwangwoo, Kim, Hiroyuki, Suetsugu, So-Young, Bang, Leilei, Wen, Masaru, Koido, Eunji, Ha, Lu, Liu, Yuma, Sakamoto, Sungsin, Jo, Rui-Xue, Leng, Nao, Otomo, Young-Chang, Kwon, Yujun, Sheng, Nobuhiko, Sugano, Mi Yeong, Hwang, Weiran, Li, Masaya, Mukai, Kyungheon, Yoon, Minglong, Cai, Kazuyoshi, Ishigaki, Won Tae, Chung, He, Huang, Daisuke, Takahashi, Shin-Seok, Lee, Mengwei, Wang, Kohei, Karino, Seung-Cheol, Shim, Xiaodong, Zheng, Tomoya, Miyamura, Young Mo, Kang, Dongqing, Ye, Junichi, Nakamura, Chang-Hee, Suh, Yuanjia, Tang, Goro, Motomura, Yong-Beom, Park, Huihua, Ding, Takeshi, Kuroda, Jung-Yoon, Choe, Chengxu, Li, Hiroaki, Niiro, Youngho, Park, Changbing, Shen, Takeshi, Miyamoto, Ga-Young, Ahn, Wenmin, Fei, Tsutomu, Takeuchi, Jung-Min, Shin, Keke, Li, Yasushi, Kawaguchi, Yeon-Kyung, Lee, Yong-Fei, Wang, Koichi, Amano, Dae Jin, Park, Wanling, Yang, Yoshifumi, Tada, Yu Lung, Lau, Ken, Yamaji, Zhengwei, Zhu, Masato, Shimizu, Takashi, Atsumi, Akari, Suzuki, Takayuki, Sumida, Yukinori, Okada, Koichi, Matsuda, Keitaro, Matsuo, Yuta, Kochi, Kazuhiko, Yamamoto, Koichiro, Ohmura, Tae-Hwan, Kim, Sen, Yang, Takuaki, Yamamoto, Bong-Jo, Kim, Nan, Shen, Shiro, Ikegawa, Hye-Soon, Lee, Xuejun, Zhang, Chikashi, Terao, Yong, Cui, and Sang-Cheol, Bae
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
ObjectiveGenome-wide association studies (GWAS) have identified >100 risk loci for systemic lupus erythematosus (SLE), but the disease genes at most loci remain unclear, hampering translation of these genetic discoveries. We aimed to prioritise genes underlying the 110 SLE loci that were identified in the latest East Asian GWAS meta-analysis.MethodsWe built gene expression predictive models in blood B cells, CD4+and CD8+T cells, monocytes, natural killer cells and peripheral blood cells of 105 Japanese individuals. We performed a transcriptome-wide association study (TWAS) using data from the latest genome-wide association meta-analysis of 208 370 East Asians and searched for candidate genes using TWAS and three data-driven computational approaches.ResultsTWAS identified 171 genes for SLE (p–5); 114 (66.7%) showed significance only in a single cell type; 127 (74.3%) were in SLE GWAS loci. TWAS identified a strong association betweenCD83and SLE (p–8). Meta-analysis of genetic associations in the existing 208 370 East Asian and additional 1498 cases and 3330 controls found a novel single-variant association at rs72836542 (OR=1.11, p=4.5×10–9) aroundCD83. For the 110 SLE loci, we identified 276 gene candidates, including 104 genes at recently-identified SLE novel loci. We demonstrated in vitro that putative causal variant rs61759532 exhibited an allele-specific regulatory effect onACAP1, and that presence of the SLE risk allele decreasedACAP1expression.ConclusionsCell-level TWAS in six types of immune cells complemented SLE gene discovery and guided the identification of novel genetic associations. The gene findings shed biological insights into SLE genetic associations.
- Published
- 2022
14. Overlapping rheumatoid meningitis with <scp>anti‐N‐methyl‐D</scp> ‐aspartate receptor encephalitis: A case report
- Author
-
Toshihiro Ide, Takeru Kawanami, Yoshifumi Tada, and Makoto Eriguchi
- Subjects
General Medicine - Published
- 2023
15. Relationships between Type 1 interferon signatures and clinical features of the new-onset lupus patients in Japan
- Author
-
Yuri Shirahama, Aki Hashimoto, Nobuyuki Ono, Yukiko Takeyama, Akihito Maruyama, Takuya Inoue, Yoshifumi Tada, and Hiroaki Niiro
- Subjects
Rheumatology - Abstract
Objectives The objective of the study is to investigate the relationships between Type 1 interferon (T1-IFN) signatures and clinical characteristics of lupus patients. Methods We examined 49 new-onset lupus patients who were diagnosed between 1999 and 2017. The patients treated with >10 mg of prednisolone or hydroxychloroquine were excluded from this study. Serum T1-IFN signatures were revealed by a functional reporter assay and standardized by recombinant IFN-α. Patient backgrounds, clinical findings, and treatments were retrospectively extracted from their electrical medical records. Clinical data were also available, including SLE Disease Activity Index of SLE patients on admission. Results T1-IFN signatures of lupus patients closely correlated with lupus disease activities, such as SLE Disease Activity Index-2K, white blood cell, C3 levels, and the titre of double-strand DNA antibody. We found fever and acute lupus dermatitis closely associated with T1-IFN signature. Conclusions In lupus patients, fever and acute lupus dermatitis are good indicators of a strong T1-IFN signature.
- Published
- 2023
16. Ultrasound efficacy of targeted-synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: a multicenter prospective cohort study in Japan
- Author
-
Yushiro Endo, Tomohiro Koga, Toshihiko Hidaka, Ayako Nishino, Remi Sumiyoshi, S.-Y. Kawashiri, Yojiro Arinobu, Akitomo Okada, Katsuhiro Ichinose, K. Fujikawa, Hideki Nakamura, Yoshifumi Tada, Tomomi Tsuru, Naoki Matsuoka, Mami Tamai, Shinya Nishihata, Hiroaki Hamada, H. Otsubo, Tamami Yoshitama, M. Nawata, S. Tsuji, Takashi Igawa, H. Takaoka, Nobutaka Eiraku, Momoko Okamoto, Toru Michitsuji, Toshimasa Shimizu, A. Kawakami, Yukitaka Ueki, Naoki Iwamoto, Tomoki Origuchi, T. Tomokawa, and Yoshika Tsuji
- Subjects
medicine.medical_specialty ,Immunology ,MEDLINE ,Disease ,Arthritis, Rheumatoid ,Japan ,Rheumatology ,Internal medicine ,medicine ,Humans ,Janus Kinase Inhibitors ,Immunology and Allergy ,Prospective Studies ,Prospective cohort study ,Ultrasonography ,business.industry ,Anti rheumatic drugs ,Ultrasound ,General Medicine ,medicine.disease ,Methotrexate ,Treatment Outcome ,Antirheumatic Agents ,Rheumatoid arthritis ,business ,Janus kinase - Abstract
This study investigated the effectiveness of treatment with Janus kinase (JAK) inhibitors in rheumatoid arthritis (RA) assessed by ultrasonography (US) activity, and the influence of patient characteristics and previous treatments.This prospective study assessed 60 treatment initiations among 53 Japanese patients diagnosed with RA who underwent treatment with JAK inhibitors during June 2013 to February 2020. Of the 53 patients, seven patients were enrolled in duplicate because they were treated with two different JAK inhibitors at different periods. For each case, the improvement rate on the power Doppler (PD) score was assessed at 6 month follow-up. Median improvement rate of PD score was used to classify cases as either US responders or non-responders, and patient characteristics were compared between the two groups.All indicators of clinical disease activity and US activity showed a significant improvement at 3 months compared with baseline. Although the JAK inhibitor-cycler group and the interleukin-6 (IL-6) inhibitor inadequate response (IR) group tended to show a later improvement for US activity, all indicators of clinical disease activity and US activity showed a significant improvement at 6 months compared with baseline for both groups. Multivariate analysis showed that concomitant methotrexate use and an IR to the previous biologic or targeted-synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) treatment were independently and significantly associated with US responders.Use of a JAK inhibitor in combination with methotrexate and an absence of IR to any previous b/tsDMARDs demonstrated superior effectiveness for patients with RA.
- Published
- 2021
17. Solving ability of Hopfield Neural Network with scale-rule noise for QAP.
- Author
-
Yoshifumi Tada, Yoko Uwate, and Yoshifumi Nishio
- Published
- 2008
- Full Text
- View/download PDF
18. Effective Search with Hopping Chaos for Hopfield Neural Networks Solving QAP.
- Author
-
Yoshifumi Tada, Yoko Uwate, and Yoshifumi Nishio
- Published
- 2007
- Full Text
- View/download PDF
19. Discrepancy between clinical and ultrasound remissions in rheumatoid arthritis: a multicentre ultrasound cohort study in Japan
- Author
-
Tamami Yoshitama, Tomohiro Koga, Remi Sumiyoshi, S.-Y. Kawashiri, Mami Tamai, Naoki Matsuoka, Katsuhiro Ichinose, Nobutaka Eiraku, Takashi Igawa, Yoshifumi Tada, Tomoki Origuchi, Yojiro Arinobu, Tomomi Tsuru, H. Otsubo, S. Tsuji, Momoko Okamoto, A. Kawakami, Akitomo Okada, Naoki Iwamoto, K. Fujikawa, Hiroaki Hamada, Yukitaka Ueki, Hideki Nakamura, Yushiro Endo, H. Takaoka, Toshihiko Hidaka, Shuji Nagano, Ayako Nishino, and Toshimasa Shimizu
- Subjects
medicine.medical_specialty ,Immunology ,MEDLINE ,Arthritis, Rheumatoid ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Rheumatology ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Ultrasonography ,030203 arthritis & rheumatology ,business.industry ,Remission Induction ,Ultrasound ,General Medicine ,medicine.disease ,Treatment Outcome ,Antirheumatic Agents ,Rheumatoid arthritis ,Cohort ,business ,Cohort study - Abstract
Objectives: Using multicentre ultrasound (US) cohort data among patients with rheumatoid arthritis (RA), we aimed to identify baseline factors that permit differentiation between two patient cohort...
- Published
- 2021
20. Immediate Effect of Baricitinib on Arthritis and Biological Disease-Modifying Antirheumatic Drug-Induced Psoriasis-Like Skin Lesions in Two Patients with Rheumatoid Arthritis
- Author
-
Syuichi Koarada, Nobuyuki Ono, and Yoshifumi Tada
- Subjects
medicine.medical_specialty ,integumentary system ,business.industry ,Abatacept ,medicine.medical_treatment ,Arthritis ,Case Report ,Diseases of the musculoskeletal system ,General Medicine ,medicine.disease ,Certolizumab ,Dermatology ,humanities ,RC925-935 ,Psoriasis ,Rheumatoid arthritis ,medicine ,Certolizumab pegol ,Disease-modifying antirheumatic drug ,Adverse effect ,business ,medicine.drug - Abstract
Biological disease-modifying antirheumatic drugs (bDMARDs) are very effective for treating rheumatoid arthritis (RA). However, they sometimes induce adverse events such as psoriasis-like skin lesions. We describe psoriasis-like skin lesions that developed simultaneously with an RA flare in patient 1 during treatment with abatacept and in patient 2 soon after starting certolizumab pegol. The skin lesions persisted in patient 2 despite stopping certolizumab. Baricitinib was initiated because of RA flare and resulted in immediate beneficial effects on arthritis as well as skin lesions. The RA went into remission in both patients, and the psoriasis-like skin lesions disappeared within four weeks (patient 1) and three months (patient 2).
- Published
- 2021
21. Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus
- Author
-
Yeon-Kyung Lee, Kohei Karino, Dae Jin Park, Xiaoting Chen, Xiaodong Zheng, Dong-Qing Ye, So-Young Bang, Leilei Wen, Tae-Hwan Kim, Takuaki Yamamoto, Yukinori Okada, Young Mo Kang, Sreeja Parameswaran, Xuejun Zhang, Cheng-Xu Li, Eunji Ha, Sang Cheol Bae, Hiroyuki Suetsugu, Koichi Amano, Tsutomu Takeuchi, Takayuki Sumida, Ken Yamaji, Hye-Soon Lee, Yuanjia Tang, Seung-Cheol Shim, Viktoryia Laurynenka, Sen Yang, Wanling Yang, Yujun Sheng, Xianyong Yin, Koichi Matsuda, Keitaro Matsuo, Akari Suzuki, Chang-Hee Suh, Weiran Li, Kwangwoo Kim, Lu Liu, Kyungheon Yoon, Bong-Jo Kim, Mi Yeong Hwang, Takeshi Kuroda, Shruti Eswar, Koichiro Ohmura, Keke Li, Tomoya Miyamura, Shiro Ikegawa, Hanan Salim, Yuta Kochi, Chikashi Terao, Won Tae Chung, Sungsin Jo, Changbing Shen, Kazuhiko Yamamoto, Daisuke Takahashi, Mengwei Wang, Masaya Mukai, Minglong Cai, Matthew T. Weirauch, Nao Otomo, Kazuyoshi Ishigaki, Yuma Sakamoto, Nan Shen, Hiroaki Niiro, Takashi Atsumi, Yong-Fei Wang, Junichi Nakamura, Young-Chang Kwon, Leah C. Kottyan, Yong Cui, John B. Harley, Goro Motomura, Masato Shimizu, Yasushi Kawaguchi, Nobuhiko Sugano, Rui-Xue Leng, Jung-Yoon Choe, Takeshi Miyamoto, Yong Beom Park, Jung-Min Shin, Masaru Koido, G.Y. Ahn, Huihua Ding, Wen-Min Fei, Shin-Seok Lee, Young-Ho Park, He Huang, and Yoshifumi Tada
- Subjects
Male ,0301 basic medicine ,Disease ,polymorphism ,0302 clinical medicine ,Japan ,Polymorphism (computer science) ,Epidemiology ,Prevalence ,Lupus Erythematosus, Systemic ,Immunology and Allergy ,skin and connective tissue diseases ,Genetics ,Asia, Eastern ,Middle Aged ,Meta-analysis ,epidemiology ,Female ,Adult ,China ,medicine.medical_specialty ,Genotype ,Immunology ,Systemic Lupus Erythematosus ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Asian People ,Rheumatology ,Republic of Korea ,medicine ,Humans ,Genetic Predisposition to Disease ,030203 arthritis & rheumatology ,Lupus erythematosus ,business.industry ,Genetic Variation ,Bayes Theorem ,systemic ,Heritability ,medicine.disease ,030104 developmental biology ,Genetic Loci ,Case-Control Studies ,Susceptibility locus ,genetic ,business ,lupus erythematosus ,Genome-Wide Association Study - Abstract
ObjectiveSystemic lupus erythematosus (SLE), an autoimmune disorder, has been associated with nearly 100 susceptibility loci. Nevertheless, these loci only partially explain SLE heritability and their putative causal variants are rarely prioritised, which make challenging to elucidate disease biology. To detect new SLE loci and causal variants, we performed the largest genome-wide meta-analysis for SLE in East Asian populations.MethodsWe newly genotyped 10 029 SLE cases and 180 167 controls and subsequently meta-analysed them jointly with 3348 SLE cases and 14 826 controls from published studies in East Asians. We further applied a Bayesian statistical approach to localise the putative causal variants for SLE associations.ResultsWe identified 113 genetic regions including 46 novel loci at genome-wide significance (p−8). Conditional analysis detected 233 association signals within these loci, which suggest widespread allelic heterogeneity. We detected genome-wide associations at six new missense variants. Bayesian statistical fine-mapping analysis prioritised the putative causal variants to a small set of variants (95% credible set size ≤10) for 28 association signals. We identified 110 putative causal variants with posterior probabilities ≥0.1 for 57 SLE loci, among which we prioritised 10 most likely putative causal variants (posterior probability ≥0.8). Linkage disequilibrium score regression detected genetic correlations for SLE with albumin/globulin ratio (rg=−0.242) and non-albumin protein (rg=0.238).ConclusionThis study reiterates the power of large-scale genome-wide meta-analysis for novel genetic discovery. These findings shed light on genetic and biological understandings of SLE.
- Published
- 2020
22. Introduction of Diagnostic Approach for Systemic Lupus Erythematosus
- Author
-
Syuichi Koarada and Yoshifumi Tada
- Published
- 2022
23. Clinical features of elderly-onset Adult-onset Still’s disease
- Author
-
Akihide Ohta, Yohei Kirino, Hideto Nagai, Yasushi Inoue, Yutaka Chifu, Syuichi Koarada, Satomi Inokuchi, Toshiyuki Ota, Yusuke Yamauchi, Masahiro Iwamoto, Akihito Maruyama, Ayako Kokuzawa, and Yoshifumi Tada
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adult-onset Still's disease ,business.industry ,health care facilities, manpower, and services ,Age Factors ,social sciences ,Disease ,Middle Aged ,Prognosis ,humanities ,Rheumatology ,medicine ,Humans ,Elderly onset ,Female ,Age of Onset ,Complication ,business ,Still's Disease, Adult-Onset ,Aged - Abstract
To clarify the characteristics of patients with elderly-onset Adult-onset Still’s disease (AOSD). Patients were classified into elderly-onset (>60 years: 47 patients) and younger-onset (≤60 years: 95 patients) groups according to their age at diagnosis of AOSD. Clinical features, treatments, and prognosis were compared between the elderly-onset and younger-onset groups. In the elderly-onset group, compared with the younger-onset group, typical skin rashes were less frequent (21.3% vs 58.9%, respectively; p p = .0011) and disseminated intravascular coagulation (19.1% vs 2.1%, respectively; p = .0004) were more frequent, and serum ferritin levels were higher (median 12,700 ng/ml vs 2526 ng/ml, respectively; p p = .0006 and p = .0023, respectively) and drug-free remission was less frequent (p = .0035) in the elderly-onset group compared with the younger-onset group. Our results demonstrated that elderly-onset AOSD patients had several characteristics that differed from younger-onset AOSD patients, including less typical skin lesions, more AOSD-related complications, higher ferritin levels, and poorer prognoses.
- Published
- 2020
24. Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study
- Author
-
Tomomi Tsuru, Tamami Yoshitama, Toshimasa Shimizu, Shinpei Morimoto, Momoko Okamoto, Shuji Nagano, Naoki Matsuoka, Ayako Nishino, Naoki Iwamoto, Kunihiro Ichinose, Remi Sumiyoshi, Akitomo Okada, K. Fujikawa, S. Tsuji, Ayuko Takatani, Yojiro Arinobu, Tomoki Origuchi, Mami Tamai, Yoshifumi Tada, S.-Y. Kawashiri, Hiroaki Hamada, Yushiro Endo, Toshihiko Hidaka, Tomohiro Koga, A. Kawakami, Takashi Igawa, Hideki Nakamura, Yukitaka Ueki, and Nobutaka Eiraku
- Subjects
Male ,musculoskeletal diseases ,Oncology ,medicine.medical_specialty ,Immunology ,Arthritis ,Autoantigens ,Abatacept ,Arthritis, Rheumatoid ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,stomatognathic system ,Rheumatology ,Antigen ,Internal medicine ,RNA, Small Cytoplasmic ,medicine ,Humans ,Immunology and Allergy ,In patient ,030212 general & internal medicine ,skin and connective tissue diseases ,Aged ,030203 arthritis & rheumatology ,biology ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,eye diseases ,stomatognathic diseases ,Ribonucleoproteins ,Antirheumatic Agents ,Rheumatoid arthritis ,biology.protein ,Female ,Antibody ,business ,Cohort study ,Anti-SSA/Ro autoantibodies ,medicine.drug - Abstract
Objective: To determine whether the positivity of baseline anti-Ro/Sjögren’s syndrome antigen A (SSA) antibodies influences the response to abatacept, we compared therapeutic responses between anti-Ro/SSA antibody-negative and -positive patients with rheumatoid arthritis (RA) using a multicentre RA ultrasonography prospective cohort. Method: We reviewed Japanese patients with RA who started abatacept as the first biological disease-modifying anti-rheumatic drug between June 2013 and April 2018. We assessed 28-joint Disease Activity Score–erythrocyte sedimentation rate (DAS28-ESR) change between baseline and 6 or 12 months after treatment in RA patients treated with abatacept, and European League Against Rheumatism (EULAR) response at 6 and 12 months. The Global OMERACT-EULAR Synovitis Score (GLOESS) was calculated at baseline and at 6 and 12 months. Results: Overall, 51 patients were enrolled and divided into anti-Ro/SSA antibody-negative and -positive groups of 35 and 16, respectively. Median age at baseline was significantly higher in the anti-Ro/SSA antibody-negative group (p = 0.04). The retention rate and percentage of EULAR good responders at 12 months were significantly higher in the anti-Ro/SSA antibody-negative group (both p = 0.02). Anti-Ro/SSA antibody-negative patients exhibited larger decreases in both DAS28-ESR and DAS28-C-reactive protein at 12 months than anti-Ro/SSA antibody-positive patients (p = 0.02 and 0.04, respectively). GLOESS decreased significantly at 6 months in anti-Ro/SSA antibody-negative patients (p = 0.03). Multivariate analyses showed that anti-Ro/SSA antibody positivity was an independent factor associated with change in the DAS28-ESR at 6 months (p Conclusion: Anti-Ro/SSA antibody positivity predicts a poor response to abatacept and low retention rate.
- Published
- 2020
25. Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan
- Author
-
Mami Tamai, Remi Sumiyoshi, Naoki Iwamoto, Hiroaki Hamada, Hideki Nakamura, Sosuke Tsuji, Takashi Igawa, Ayuko Takatani, Tamami Yoshitama, Toshimasa Shimizu, Yojiro Arinobu, Atsushi Kawakami, Ayako Nishino, Yukitaka Ueki, Shuji Nagano, Keita Fujikawa, Shimpei Morimoto, Shin-ya Kawashiri, Tomoki Origuchi, Nobutaka Eiraku, Yushiro Endo, Tomohiro Koga, Tomomi Tsuru, Kunihiro Ichinose, Toshihiko Hidaka, Akitomo Okada, Yoshifumi Tada, Naoki Matsuoka, and Momoko Okamoto
- Subjects
Male ,rheumatoid arthritis ,lcsh:Immunologic diseases. Allergy ,medicine.medical_specialty ,retention ,Necrosis ,non-tumour necrosis factor inhibitor ,medicine.medical_treatment ,Immunology ,tumour necrosis factor inhibitor ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,Abatacept ,Arthritis, Rheumatoid ,Cohort Studies ,Japan ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,In patient ,Prospective Studies ,Prospective cohort study ,Aged ,Ultrasonography ,doppler ultrasonography ,business.industry ,Drug Substitution ,Middle Aged ,medicine.disease ,TNF inhibitor ,Treatment Outcome ,Rheumatoid arthritis ,Antirheumatic Agents ,Female ,Tumor Necrosis Factor Inhibitors ,medicine.symptom ,business ,lcsh:RC581-607 - Abstract
To compare therapeutic efficacy of tumour necrosis factor inhibitor (TNFi) cyclers and non-TNFi switchers in patients with rheumatoid arthritis (RA) having inadequate response to previous TNFis (TNF-IR patients) using composite measures including imaging assessment with power Doppler ultrasonography (PDUS). Patients with RA who had inadequate response to one or more previous TNFi agents with moderate or higher disease activity were enrolled. The outcomes of 56 TNF-IR patients were analysed. Patients were divided into 19 TNFi cyclers and 37 non-TNFi switchers (16 abatacept [ABT] and 21 tocilizumab [TCZ] switchers). Retention ratio at 6 months was significantly higher in non-TNFi switchers than in TNFi cyclers (p
- Published
- 2020
26. The complete mitochondrial genome of Sarcoptes scabiei var. nyctereutis from the Japanese raccoon dog: Prediction and detection of two transfer RNAs (tRNA-A and tRNA-Y)
- Author
-
Keitaro Imaizumi, Minori Kawahara, Takashi Abe, Nobuhide Kido, Masataka Nakagawa, Daisuke Minegishi, Takane Kikuchi-Ueda, Yasuo Ono, Sohei Tanaka, Yoshifumi Tada, Kouki Morikaku, Teruo Akuta, Takafumi Ueda, Hiroshi Tarui, Tomoko Omiya, and Kenji Hikosaka
- Subjects
0106 biological sciences ,Mitochondrial DNA ,RNA, Transfer, Ala ,Biology ,Sarcoptes scabiei ,01 natural sciences ,Genome ,03 medical and health sciences ,parasitic diseases ,Genetics ,Mite ,Animals ,Gene ,Phylogeny ,030304 developmental biology ,0303 health sciences ,integumentary system ,Ribosomal RNA ,Raccoon Dogs ,biology.organism_classification ,Sarcoptidae ,RNA, Transfer, Tyr ,Genome, Mitochondrial ,Transfer RNA ,010606 plant biology & botany - Abstract
Sarcoptes scabiei (Acari: Sarcoptidae) causes a common contagious skin disease that affects many mammals. Here, the complete mitochondrial genome of a mite, S. scabiei var. nyctereutis, from Japanese wild raccoon dogs was analyzed. The 13,837bp circular genome contained 13 protein-coding genes, two rRNA genes, and 22 tRNA genes. For the first time, two tRNAs (alanine and tyrosine), that were thought to be absent in scabies mites from other animals, were predicted to have short, non-cloverleaf structures by in silico annotation and detected by RT-PCR, sequencing, and northern analysis. The mitochondrial genome structure of S. scabiei is similar to that of Psoroptes cuniculi and Dermatophagoides farinae. While small and unusual tRNA genes seem to be common among acariform mites, further experimental evidence for their presence is needed. Furthermore, through an analysis of the cox1 gene, we have provided new evidence to confirm the transmission of this mite between different animal hosts.
- Published
- 2019
27. Identification of lipophilic ligands of Siglec5 and -14 that modulate innate immune responses
- Author
-
Yoshifumi Tada, Tomofumi Miyamoto, Sho Yamasaki, Hiroki Yoshida, Rie Suematsu, Yasunobu Miyake, and Shinobu Saijo
- Subjects
0301 basic medicine ,Glycan ,Antigens, Differentiation, Myelomonocytic ,Receptors, Cell Surface ,Ligands ,Biochemistry ,Cell Line ,Fungal Proteins ,03 medical and health sciences ,chemistry.chemical_compound ,Trichophyton ,Antigens, CD ,Lectins ,Alkanes ,Cardiolipin ,Humans ,Receptor ,Molecular Biology ,Triglycerides ,Innate immune system ,030102 biochemistry & molecular biology ,biology ,SIGLEC ,Cell Biology ,Ligand (biochemistry) ,Immunity, Innate ,Sialic acid ,030104 developmental biology ,chemistry ,biology.protein ,Cell activation ,Hydrophobic and Hydrophilic Interactions - Abstract
Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of cell-surface immune receptors that bind to sialic acid at terminal glycan residues. Siglecs also recognize nonsialic acid ligands, many of which remain to be characterized. Here, we found that Siglec5 and Siglec14 recognize lipid compounds produced by Trichophyton, a fungal genus containing several pathogenic species. Biochemical approaches revealed that the Siglec ligands are fungal alkanes and triacylglycerols, an unexpected finding that prompted us to search for endogenous lipid ligands of Siglecs. Siglec5 weakly recognized several endogenous lipids, but the mitochondrial lipid cardiolipin and the anti-inflammatory lipid 5-palmitic acid-hydroxystearic acid exhibited potent ligand activity on Siglec5. Further, the hydrophobic stretch in the Siglec5 N terminus region was found to be required for efficient recognition of these lipids. Notably, this hydrophobic stretch was dispensable for recognition of sialic acid. Siglec5 inhibited cell activation upon ligand binding, and accordingly, the lipophilic ligands suppressed interleukin-8 (IL-8) production in Siglec5-expressing human monocytic cells. Siglec14 and Siglec5 have high sequence identity in the extracellular region, and Siglec14 also recognized the endogenous lipids. However, unlike Siglec5, Siglec14 transduces activating signals upon ligand recognition. Indeed, the endogenous lipids induced IL-8 production in Siglec14-expressing human monocytic cells. These results indicated that Siglec5 and Siglec14 can recognize lipophilic ligands that thereby modulate innate immune responses. To our knowledge, this is the first study reporting the binding of Siglecs to lipid ligands, expanding our understanding of the biological function and importance of Siglecs in the innate immunity.
- Published
- 2019
28. Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus
- Author
-
Takahiro Okawa, Hiroyuki Suetsugu, Tomoya Miyamura, So-Young Bang, Tomokazu Yoshioka, Yoshiya Tanaka, Akari Suzuki, Chikashi Terao, Koichi Amano, Takeshi Kuroda, Hiroaki Niiro, Koichi Matsuda, Bong-Jo Kim, Takashi Atsumi, Masaya Mukai, Tomomichi Kajino, Katsunori Ikari, Goro Motomura, Junichi Nakamura, Masaru Koido, Young-Chang Kwon, Yohei Naito, Yuta Kochi, Ayumi Kaneuji, G.Y. Ahn, Koichiro Ohmura, Yuji Yasunaga, Yeon-Kyung Lee, Kohei Karino, Ryo Hisada, Takuaki Yamamoto, Shiro Ikegawa, Mihoko Yamazaki, Kohei Tomizuka, Nobuhiko Sugano, Kenji Ohzono, Jihye Kim, Masato Shimizu, Takeshi Miyamoto, Sang Cheol Bae, Yoichi Ohta, Tsutomu Takeuchi, Tamon Kabata, Jung-Min Shin, Ken Yamaji, Kwangwoo Kim, Hye-Soon Lee, Taisuke Seki, Toshikazu Kubo, Yoshifumi Tada, Ji Soong Kim, Daisuke Takahashi, Yukinori Okada, Yuma Sakamoto, and Dae Jin Park
- Subjects
medicine.medical_treatment ,Genome-wide association study ,Disease ,Carboxypeptidases ,Biology ,Polymorphism, Single Nucleotide ,Steroid ,Femoral head ,Femur Head Necrosis ,Genetics ,medicine ,Humans ,Lupus Erythematosus, Systemic ,Genetic Predisposition to Disease ,Molecular Biology ,Gene ,Allele frequency ,Genetics (clinical) ,Myosin Heavy Chains ,Femur Head ,General Medicine ,MicroRNAs ,medicine.anatomical_structure ,Immunology ,Etiology ,Steroids ,Bone marrow ,Carrier Proteins ,Bioinformatics Article ,Genome-Wide Association Study - Abstract
Osteonecrosis of the femoral head (ONFH) involves necrosis of bone and bone marrow of the femoral head caused by ischemia with unknown etiology. Previous genetic studies on ONFH failed to produce consistent results, presumably because ONFH has various causes with different genetic backgrounds and the underlying diseases confounded the associations. Steroid-associated ONFH (S-ONFH) accounts for one-half of all ONFH, and systemic lupus erythematosus (SLE) is a representative disease underlying S-ONFH. We performed a genome-wide association study (GWAS) to identify genetic risk factors for S-ONFH in patients with SLE. We conducted a two-staged GWAS on 636 SLE patients with S-ONFH and 95 588 non-SLE controls. Among the novel loci identified, we determined S-ONFH-specific loci by comparing allele frequencies between SLE patients without S-ONFH and non-SLE controls. We also used Korean datasets comprising 148 S-ONFH cases and 37 015 controls to assess overall significance. We evaluated the functional annotations of significant variants by in silico analyses. The Japanese GWAS identified 4 significant loci together with 12 known SLE susceptibility loci. The four significant variants showed comparable effect sizes on S-ONFH compared with SLE controls and non-SLE controls. Three of the four loci, MIR4293/MIR1265 [odds ratio (OR) = 1.99, P-value = 1.1 × 10−9)], TRIM49/NAALAD2 (OR = 1.65, P-value = 4.8 × 10−8) and MYO16 (OR = 3.91, P-value = 4.9 × 10−10), showed significant associations in the meta-analysis with Korean datasets. Bioinformatics analyses identified MIR4293, NAALAD2 and MYO16 as candidate causal genes. MIR4293 regulates a PPARG-related adipogenesis pathway relevant to S-ONFH. We identified three novel susceptibility loci for S-ONFH in SLE.
- Published
- 2021
29. Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study
- Author
-
Shinichi Mizuki, Tomomi Tsuru, Yasutaka Kimoto, Shun-ichiro Ota, Shigeru Yoshizawa, Hiroaki Niiro, Kensuke Oryoji, Shuji Nagano, Yasuo Suenaga, Seiji Yoshizawa, Yoshifumi Tada, Takuya Sawabe, Koichi Akashi, Tomoya Miyamura, Naoyasu Ueda, Yasushi Inoue, Chikako Kiyohara, Takahiko Horiuchi, Hiroaki Nishizaka, and Yusuke Kashiwado
- Subjects
medicine.medical_specialty ,business.industry ,Clinical course ,Retrospective cohort study ,medicine.disease ,Arthritis, Rheumatoid ,Biological Therapy ,Hospitalization ,Risk Factors ,Internal medicine ,Rheumatoid arthritis ,medicine ,Humans ,business ,Retrospective Studies - Abstract
Background To analyse the subsequent clinical course of patients with rheumatoid arthritis (RA) who either continued or discontinued biologic agents after hospitalization for infections. Methods We retrospectively reviewed the clinical records of 230 RA patients with 307 hospitalizations for infections under biologic therapy between September 2008 and May 2014 in 15 institutions for up to 18 months after discharge. The risks of RA flares and subsequent hospitalizations for infections from 61 days to 18 months after discharge were evaluated. Results Survival analyses indicated that patients who continued biologic therapy had a significantly lower risk of RA flares (31.4% vs. 60.6%, P P = 0.37). Multivariate analysis showed that discontinuation of biologic therapy, diabetes, and a history of hospitalization for infection under biologic therapy were associated with RA flares. Oral steroid therapy equivalent to prednisolone 5 mg/day or more and chronic renal dysfunction were independent risk factors for subsequent hospitalizations for infections. Conclusions Discontinuation of biologic therapy after hospitalization for infections may result in RA flares. Continuation of biologic therapy is preferable, particularly in patients without immunodeficiency.
- Published
- 2021
30. Usefulness of the severity classification for predicting drug-free remission in Japanese patients with adult-onset Still's disease
- Author
-
Akihito Maruyama, Ayako Kokuzawa, Yusuke Yamauchi, Yohei Kirino, Hideto Nagai, Yasushi Inoue, Toshiyuki Ota, Yutaka Chifu, Satomi Inokuchi, Hiroki Mitoma, Mitsuteru Akahoshi, Mariko Sakai, Akihide Ohta, Masahiro Iwamoto, and Yoshifumi Tada
- Subjects
Adult ,Rheumatology ,Japan ,Humans ,macromolecular substances ,Still's Disease, Adult-Onset ,Retrospective Studies - Abstract
Objectives To investigate the usefulness of severity classification for predicting outcomes in patients with adult-onset Still’s disease (AOSD). Methods This was a multi-centre retrospective cohort study. AOSD patients were classified into mild, moderate, and severe groups based on severity classification (Japanese Ministry of Health, Labour and Welfare) during the initial treatment, and clinical features were compared among these groups. The primary endpoints were the AOSD-related mortality and drug-free remission rate. For comparison, the same analysis was performed in parallel for patient groups stratified by the modified Pouchot systemic score. Results According to severity classification, 49 (35%), 37 (26%), and 56 patients (39%) were classified into mild, moderate, and severe groups, respectively. Patients in the severe group showed higher frequency of severe complications and the use of biological agents. Although AOSD-related survival was not significantly different (p = .0776), four of the five fatal cases were classified into the severe group. The severe group showed a reduced rate of drug-free remission (p = .0125). Patient groups classified by systemic score did not correlate with survival or drug-free remission. Conclusions Severity classification is useful for predicting outcomes in patients with AOSD.
- Published
- 2021
31. Performance of chaotic switching noise injected to Hopfield NN for quadratic assignment problem.
- Author
-
Yoshifumi Tada, Yoko Uwate, and Yoshifumi Nishio
- Published
- 2006
- Full Text
- View/download PDF
32. The Association of Airway Comorbidities With the Clinical Phenotypes and Outcomes of Patients With Antineutrophil Cytoplasmic Autoantibody–associated Vasculitis
- Author
-
Yukiko Takeyama, Shuji Nagano, Takuya Sawabe, Nobuyuki Ono, Kensuke Oryoji, Yasutaka Kimoto, Tomoya Miyamura, Hisako Inoue, Naoyasu Ueda, Katsuhisa Miyake, Hitoshi Nakashima, Hiroaki Niiro, Yoshifumi Tada, Shun Ichiro Ota, Ayako Takamori, Yasushi Inoue, Seiji Yoshizawa, Takahiko Horiuchi, and Yuri Sadanaga
- Subjects
medicine.medical_specialty ,Myeloblastin ,Immunology ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ,Comorbidity ,Gastroenterology ,Antibodies, Antineutrophil Cytoplasmic ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Internal medicine ,Eosinophilic ,medicine ,Humans ,Immunology and Allergy ,Aged ,Peroxidase ,030203 arthritis & rheumatology ,Bronchiectasis ,business.industry ,Granulomatosis with Polyangiitis ,Autoantibody ,Interstitial lung disease ,medicine.disease ,respiratory tract diseases ,Phenotype ,030228 respiratory system ,Cohort ,Vasculitis ,business ,Airway - Abstract
Objective.We investigated the association of airway comorbidities with the clinical phenotypes and outcomes of myeloperoxidase (MPO)–antineutrophil cytoplasmic antibodies (ANCA)–positive ANCA-associated vasculitis (AAV).Methods.An AAV patient multicenter cohort trial was established in 13 hospitals in western Japan between 2012 and 2018. We examined 143 of the new-onset MPO-ANCA–positive AAV patients. Their clinical characteristics and comorbidities at disease onset were compared based on clinical phenotypes. Multivariate analysis was performed to identify factors predictive of remission and death.Results.Twenty-seven cases with granulomatosis with polyangiitis (GPA), 10 with eosinophilic GPA (EGPA), 81 with microscopic polyangiitis (MPA), and 25 with unclassified AAV were identified. The average age of MPO-ANCA–positive patients was 71.4 years. Comorbidity (87.4%) and airway comorbidity (70.6%) were frequently observed in these patients. Examination of the clinical phenotypes revealed that the cases of GPA were frequently accompanied by infectious airway comorbidity (upper airway disease, bronchiectasis, pulmonary infections), and most of the cases of MPA and unclassified AAV were accompanied by fibrotic interstitial lung disease (fILD) or emphysema. Among MPO-ANCA–positive patients, infectious airway comorbidity was predictive of both remission (HR 1.58, P = 0.03) and mortality (HR 2.64, P = 0.04), and fILD was predictive of mortality (HR 7.55, P = 0.008). The combination of infectious airway comorbidities and fILD caused the worst survival outcomes in patients.Conclusion.MPO-ANCA–positive AAV was frequently accompanied by airway comorbidities. In addition to fILD, infectious airway comorbidities were closely associated with those clinical phenotypes and outcomes.
- Published
- 2019
33. Development of a rapid scabies immunodiagnostic assay based on transcriptomic analysis of Sarcoptes scabiei var. nyctereutis
- Author
-
Yuki Oouchi, Chiaki Sakuma, Minori Kawahara, Hiroshi Tarui, Yasuo Ono, Daisuke Minegishi, Fumi Hori, Keitaro Imaizumi, Teruo Akuta, Nakagawa, Kenji Hikosaka, Tomoko Omiya, Yoshifumi Tada, Shin-Ichiro Tachibana, Kouki Morikaku, Nobuhide Kido, Shinji Nakaoka, Takane Kikuchi-Ueda, Yu Nakajima, Takafumi Ueda, Sohei Tanaka, and Masataka
- Subjects
0301 basic medicine ,Evolution ,Molecular biology ,Science ,030231 tropical medicine ,Hypothetical protein ,Mange ,Diseases ,Sarcoptes scabiei ,Immunologic Tests ,Biochemistry ,Article ,Arthropod Proteins ,03 medical and health sciences ,Scabies ,0302 clinical medicine ,Medical research ,parasitic diseases ,Mite ,medicine ,Animals ,Skin ,Multidisciplinary ,biology ,integumentary system ,Molecular medicine ,Biological techniques ,Raccoon Dogs ,Allergens ,biology.organism_classification ,medicine.disease ,Virology ,Specific antibody ,030104 developmental biology ,Medicine ,Transcriptome ,Biomarkers ,Lateral flow immunoassay ,Biotechnology - Abstract
Scabies is a highly contagious skin disease caused by the mite Sarcoptes scabiei that affects many mammals. However, the sensitivity of traditional tests for scabies diagnosis in humans is less than 50%. To simplify the diagnosis of scabies, methods that are simple, sensitive, specific, and cost-effective are required. We developed an immunodiagnostic test based on S. scabiei var. nyctereutis RNA-seq data collected from Japanese raccoon dogs with sarcoptic mange. Three candidate antigens—a highly expressed hypothetical protein “QR98_0091190,” another mite allergen known as “SMIPP-Cc,” and an abundant “vitellogenin-like protein”—were evaluated by western-blot analysis. A lateral flow immunoassay, using specific antibodies against the vitellogenin-like protein, successfully detected scabies in the skin flakes of S. scabiei-infected raccoon dogs. This assay can potentially diagnose scabies more accurately in wildlife, as well as in humans.
- Published
- 2021
34. Usefulness of the severity classification for predicting drug-free remission in Japanese patients with adult-onset Still's disease.
- Author
-
Akihito Maruyama, Ayako Kokuzawa, Yusuke Yamauchi, Yohei Kirino, Hideto Nagai, Yasushi Inoue, Toshiyuki Ota, Yutaka Chifu, Satomi Inokuchi, Hiroki Mitoma, Mitsuteru Akahoshi, Mariko Sakai, Akihide Ohta, Masahiro Iwamoto, and Yoshifumi Tada
- Subjects
STILL'S disease ,JAPANESE people - Abstract
Objectives: To investigate the usefulness of severity classification for predicting outcomes in patients with adult-onset Still's disease (AOSD). Methods: This was a multi-centre retrospective cohort study. AOSD patients were classified into mild, moderate, and severe groups based on severity classification (Japanese Ministry of Health, Labour and Welfare) during the initial treatment, and clinical features were compared among these groups. The primary endpoints were the AOSD-related mortality and drug-free remission rate. For comparison, the same analysis was performed in parallel for patient groups stratified by the modified Pouchot systemic score. Results: According to severity classification, 49 (35%), 37 (26%), and 56 patients (39%) were classified into mild, moderate, and severe groups, respectively. Patients in the severe group showed higher frequency of severe complications and the use of biological agents. Although AOSDrelated survival was not significantly different (p=.0776), four of the five fatal cases were classified into the severe group. The severe group showed a reduced rate of drug-free remission (p=.0125). Patient groups classified by systemic score did not correlate with survival or drug-free remission. Conclusions: Severity classification is useful for predicting outcomes in patients with AOSD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Association Between Serum Bone Biomarker Levels and Therapeutic Response to Abatacept in Patients With Rheumatoid Arthritis (Ra): a Multicenter Ra Ultrasound Prospective Cohort Study in Japan
- Author
-
Shin-Ya Kawashiri, Yushiro Endo, Ayako Nishino, Momoko Okamoto, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Remi Sumiyoshi, Tomohiro Koga, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Toshiyuki Aramaki, Yukitaka Ueki, Tamami Yoshitama, Nobutaka Eiraku, Naoki Matsuoka, Akitomo Okada, Keita Fujikawa, Hiroaki Hamada, Shuji Nagano, Yoshifumi Tada, and Atsushi Kawakami
- Subjects
musculoskeletal diseases - Abstract
Background: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept.Methods: We enrolled 59 RA patients treated with abatacept from a multicenter prospective ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients' clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. 'Power Doppler (PD) responder' was defined as a patient whose Δtotal PD score over 6 months was greater than the median change.Results: Abatacept significantly improved clinical disease activity as well as the MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the introduction of abatacept (p=0.016). The ΔSOST and ΔOPG values were negatively correlated with the Δtotal PD score (rs= −0.31, pConclusion: Serum levels of bone biomarkers may be useful for predicting RA patients' therapeutic response to abatacept.Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort studyTrial registration number: UMIN000012524Date of registration: 12/9/2013URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657
- Published
- 2020
36. Meta-analysis of 208,370 East Asians identifies 113 genomic loci and yields new non-immune cell relevant biological insights for systemic lupus erythematosus
- Author
-
Leilei Wen, Tomoya Miyamura, Xiaodong Zheng, So-Young Bang, Eunji Ha, Cheng-Xu Li, Sungsin Jo, Changbing Shen, Weiran Li, Yukinori Okada, Koichiro Ohmura, Shruti Eswar, Ken Yamaji, Sen Yang, Huihua Ding, Takayuki Sumida, Chang-Hee Suh, Seung-Cheol Shim, Yuta Kochi, Tae-Hwan Kim, Takuaki Yamamoto, Won Tae Chung, Yong Beom Park, Masaru Koido, John B. Harley, Goro Motomura, Yujun Sheng, G.Y. Ahn, Jung-Yoon Choe, Takeshi Miyamoto, Rui-Xue Leng, Xuejun Zhang, Takashi Atsumi, Chikashi Terao, Jung-Min Shin, Yoshifumi Tada, Xiaoting Chen, Young-Ho Park, Nobuhiko Sugano, He Huang, Keitaro Matsuo, Hiroaki Niiro, Hanan Salim, Leah C. Kottyan, Young Mo Kang, Masaya Mukai, Yong Cui, Junichi Nakamura, Young-Chang Kwon, Yeon-Kyung Lee, Minglong Cai, Sreeja Parameswaran, Wanling Yang, Kwangwoo Kim, Mi Yeong Hwang, Takeshi Kuroda, Masato Shimizu, Yasushi Kawaguchi, Xianyong Yin, Kyungheon Yoon, Daisuke Takahashi, Sang Cheol Bae, Keke Li, Hye-Soon Lee, Matthew T. Weirauch, Yuma Sakamoto, Nao Otomo, Tsutomu Takeuchi, Yuanjia Tang, Kohei Karino, Koichi Matsuda, Bong-Jo Kim, Shiro Ikegawa, Nan Shen, Wen-Min Fei, Hiroyuki Suetsugu, Lu Liu, Akari Suzuki, Dong-Qing Ye, Mengwei Wang, Kazuhiko Yamamoto, Yong-Fei Wang, Viktoryia Laurynenka, Shin-Seok Lee, Koichi Amano, and Kazuyoshi Ishigaki
- Subjects
Genetics ,Drug repositioning ,Immune system ,medicine.anatomical_structure ,Effector ,Cell ,medicine ,Missense mutation ,Heritability ,Biology ,Gene ,In vitro - Abstract
Systemic lupus erythematosus (SLE), an autoimmune disorder, has been associated with nearly 100 susceptibility loci1-8. Nevertheless, these loci only partially explain SLE heritability and provide limited biological insight. We report the largest study of SLE in East Asians (13,377 cases and 194,993 controls), identifying 233 association signals within 113 (46 novel) genetic loci. We detect six new lead missense variants and prioritize ten most likely putative causal variants, one of which we demonstrate exhibits allele-specific regulatory effect on ACAP1 in vitro. We suggest 677 effector genes with potential for drug repurposing, and provide evidence that two distinct association signals at a single locus act on different genes (NCF2 and SMG7). We demonstrate that SLE-risk variants overlap with cell-specific active regulatory elements, notably EBNA2-mediated super-enhancers in Epstein-Barr Virus-transformed B cells, and implicate the role for non-immune cells in SLE biology. These findings shed light on genetic and biological understandings of SLE.
- Published
- 2020
37. Rituximab maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis in Japan
- Author
-
Kensuke Oryoji, Hiroki Mitoma, Yuri Shirahama, Takuya Sawabe, Naoya Nishimura, Naoyasu Ueda, Hiroaki Niiro, Naoko Himuro, Yasushi Inoue, Akihito Maruyama, Yasutaka Kimoto, Takahiko Horiuchi, Katsuhisa Miyake, Atsushi Tanaka, Ayumi Uchino, Shuji Nagano, Hisako Inoue, Yoshifumi Tada, Seiji Yoshizawa, Nobuyuki Ono, Tomoya Miyamura, Yukiko Takeyama, Ayako Takamori, and Shun Ichiro Ota
- Subjects
Adult ,Male ,ANCA-Associated Vasculitis ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ,urologic and male genital diseases ,Rheumatology ,Maintenance therapy ,immune system diseases ,Recurrence ,Medicine ,Humans ,cardiovascular diseases ,skin and connective tissue diseases ,Anti-neutrophil cytoplasmic antibody ,business.industry ,Middle Aged ,medicine.disease ,respiratory tract diseases ,Antirheumatic Agents ,Immunology ,Rituximab ,Female ,business ,Vasculitis ,medicine.drug - Abstract
We examined the efficacy and safety of rituximab (RTX) maintenance therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in Japan.We conducted a retrospective study using a multi-center cohort database of vasculitis patients. All maintenance treatment courses were divided into three groups: a RTX group, a group treated with other immunosuppressant drugs (IS) and a group receiving glucocorticoid monotherapy (GC). The primary endpoint was the comparison of relapse-free survival after 1 year. We also analyzed the occurrence of severe adverse events (SAEs) to assess safety.We included 123 courses of 107 patients (RTXRTX maintenance therapy could be effective and safe in Japanese GPA patients.
- Published
- 2020
38. Association between serum bone biomarker levels and ultrasonographic response in abatacept-treated rheumatoid arthritis patients
- Author
-
Shin-Ya Kawashiri, Yushiro Endo, Ayako Nishino, Momoko Okamoto, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Remi Sumiyoshi, Tomohiro Koga, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Toshiyuki Aramaki, Yukitaka Ueki, Tamami Yoshitama, Nobutaka Eiraku, Naoki Matsuoka, Akitomo Okada, Keita Fujikawa, Hiroaki Hamada, Shuji Nagano, Yoshifumi Tada, Takahiro Maeda, and Atsushi Kawakami
- Subjects
musculoskeletal diseases - Abstract
Background To evaluate the effect of treatment on bone biomarkers and explore whether bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. Methods We enrolled 59 RA patients treated with abatacept from a multicenter prospective ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients' clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. 'Power Doppler (PD) responder' was defined as a patient whose Δtotal PD score over 6 months was greater than the median change. Results Abatacept significantly improved clinical disease activity as well as the MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the introduction of abatacept (p = 0.016). The ΔSOST and ΔOPG values were negatively correlated with the Δtotal PD score (rs = − 0.31, p
- Published
- 2020
39. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients
- Author
-
Akihito Maruyama, Takuya Inoue, Keita Kai, Yoshifumi Tada, Mariko Sakai, Yuri Sadanaga, Shuichi Koarada, and Nobuyuki Ono
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Interferon-Induced Helicase, IFIH1 ,Dermatomyositis ,Amino Acyl-tRNA Synthetases ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Dermis ,medicine ,Humans ,Pharmacology (medical) ,Vascular Diseases ,030212 general & internal medicine ,Myositis ,Autoantibodies ,030203 arthritis & rheumatology ,business.industry ,Mononeuritis Multiplex ,Melanoma ,Interstitial lung disease ,Middle Aged ,Skin ulcer ,medicine.disease ,medicine.anatomical_structure ,Interferon Type I ,Immunohistochemistry ,Female ,medicine.symptom ,Lung Diseases, Interstitial ,business - Abstract
Objective Based on the antibody profiles of inflammatory myositis patients, we investigated the type 1 IFN (T1-IFN) signature in serum and DM skin to determine the relationship between T1-IFN and vasculopathy in anti-melanoma differentiation-associated 5 gene (MDA5) antibody-positive DM patients. Methods We examined 47 patients with new-onset inflammatory myositis. We divided them into three groups: the anti-MDA5 antibody-positive patients (MDA5 group, n = 16), the anti-aminoacyl-tRNA synthetase antibody-positive patients (aminoacyl-tRNA synthetase group, n = 12), and the double-negative patients (n = 19). Serum T1-IFN signatures were revealed by a functional reporter assay, and we evaluated the T1-IFN signatures of skin based on Mx1 expression by immunohistochemistry. Results The numbers of patients with classical DM, clinically amyopathic DM and interstitial lung disease were 1, 15 and 13 in the MDA5 group, 2, 3 and 11 in the aminoacyl-tRNA synthetase group, and 10, 1 and 4 in the double-negative group, respectively. The signs of vasculopathies (i.e. palmer papules, skin ulcers and mononeuritis multiplex) were identified only in the MDA5 patients. Most of the MDA5 group showed the highest serum T1-IFN signatures among the three groups. In the histological analysis of DM skin, perivascular inflammations were significant in the MDA5 group. The MDA5 group’s Mx1 expression was significantly strong, distributed in blood vessels and interstitial fibroblasts, and had spread to deep dermis. Conclusion Anti-MDA5 antibody-positive DM patients showed high T1-IFN signatures in serum and affected skin. The high T1-IFN signatures of the MDA5 antibody-positive DM patients in serum and deep vasculatures suggested that T1-IFN may have important roles in the vasculopathy of these patients.
- Published
- 2020
40. Effect of abatacept treatment on serum osteoclast-related biomarkers in patients with rheumatoid arthritis (RA)
- Author
-
Toshiyuki Aramaki, Ayuko Takatani, Sosuke Tsuji, Yushiro Endo, Tomoki Origuchi, Toshimasa Shimizu, Ayako Nishino, Atsushi Kawakami, Naoki Iwamoto, Tamami Yoshitama, Hiroaki Hamada, Yukitaka Ueki, Remi Sumiyoshi, Keita Fujikawa, Nobutaka Eiraku, Tomohiro Koga, Hideki Nakamura, Yoshifumi Tada, Kunihiro Ichinose, Momoko Okamoto, Akitomo Okada, Naoki Matsuoka, Shin-ya Kawashiri, Mami Tamai, and Shuji Nagano
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,business.industry ,Abatacept ,Ultrasound ,Arthritis ,General Medicine ,medicine.disease ,Gastroenterology ,Pharmacotherapy ,Rheumatoid arthritis ,Internal medicine ,Severity of illness ,medicine ,business ,Prospective cohort study ,Cohort study ,medicine.drug - Abstract
We evaluated the effect of abatacept treatment on osteoclast-related biomarkers and explored whether the biomarkers are associated with the therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept.We enrolled 44 RA patients treated with abatacept from a multicenter prospective ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug therapy. We evaluated the disease activity score (DAS) 28-CRP (C-reactive protein), musculoskeletal ultrasound scores including the total grayscale score (GS)/power Doppler (PD) score and the serum concentrations of isoform 5b of tartrate-resistant acid phosphate (TRACP-5b) and soluble receptor activator of nuclear factor-κB ligand (sRANKL) at baseline and at 3 and 6 months of treatment. "PD responder" was defined as a patient whose Δtotal PD score over 6 months was greater than the median change of that.Abatacept significantly improved DAS28-CRP as well as the total GS/PD score over 6 months. Serum TRACP-5b was significantly elevated and serum sRANKL was significantly decreased at 6 months (P
- Published
- 2021
41. A case of granulomatosis with polyangiitis accompanied with strawberry gingivitis, and a review of the literatures
- Author
-
Yukiko Tokuda, Mariko Sakai, Syuichi Koarada, Rie Suematsu, Yoshifumi Tada, Nobuyuki Ono, Hiromi Kimura, Akihito Maruyama, Yuri Sadanaga, and Daiji Shimohira
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,macromolecular substances ,medicine.disease ,Gingivitis ,Swollen gums ,stomatognathic system ,Medicine ,medicine.symptom ,Strawberry gingivitis ,business ,Vasculitis ,Granulomatosis with polyangiitis - Abstract
Hyperplastic granular gingivitis, also known as “strawberry gingivitis” (SG), is a characteristic oral presentation of granulomatosis with polyangiitis (GPA). We report a case of a 38-year-...
- Published
- 2017
42. Characteristics and prognosis of microscopic polyangiitis with bronchiectasis
- Author
-
Kazutoshi Komiya, Koichiro Takahashi, Tomomi Nakamura, Hiroki Tashiro, Naoko Sueoka-Aragane, Shinya Kimura, Masahide Tanaka, and Yoshifumi Tada
- Subjects
030203 arthritis & rheumatology ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Bronchiectasis ,business.industry ,Pulmonary infection ,Diffuse alveolar hemorrhage ,medicine.disease ,Gastroenterology ,humanities ,Surgery ,03 medical and health sciences ,Pneumonia ,0302 clinical medicine ,030228 respiratory system ,Internal medicine ,Medicine ,Original Article ,Interstitial pneumonia ,business ,Microscopic polyangiitis ,Complication ,Lower mortality - Abstract
Background: Major pulmonary manifestations associated with microscopic polyangiitis (MPA) include diffuse alveolar hemorrhage (DAH) and interstitial pneumonia (IP).We previously showed bronchiectasis (BE) was one of the pulmonary complications of MPA. However, clinical features of BE patients with MPA are not fully understood. We investigated the characteristics and prognosis of BE patients with MPA. Methods: Forty-five MPA patients were retrospectively studied. The patients were divided into two groups: patients with BE and those without BE. Results: Thirty-one of 45 patients (69%) had pulmonary involvement including IP (23/45, 51%), BE (7/45, 16%), and DAH (5/45, 11%). There were no differences between the patients with BE versus those without with regard to clinical characteristics and initial treatments. However, the prognosis for patients with BE was better than those without BE during the first year after diagnosis, but it was worse between 1 and 5 years, which was statistically significant. Two BE patients died between 1 and 5 years as a result of pneumonia. Conclusions: BE as a complication of MPA might be related to lower mortality in the acute phase and higher mortality in the chronic phase compared to other pulmonary manifestations. More attention to pulmonary infection is needed for patients with BE during the chronic phase.
- Published
- 2017
43. Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan
- Author
-
Ayako Nishino, Mizuna Eguchi, Kunihiro Ichinose, Akitomo Okada, K. Fujikawa, Toshimasa Shimizu, Ayuko Takatani, Momoko Okamoto, Tomomi Tsuru, Atsushi Kawakami, Yojiro Arinobu, Hiroaki Hamada, Mami Tamai, Yoshifumi Tada, Naoki Matsuoka, Tomohiro Koga, S. Tsuji, Shimpei Morimoto, Yushiro Endo, Shin-ya Kawashiri, Takashi Igawa, Toshihiko Hidaka, Hideki Nakamura, Remi Sumiyoshi, Naoki Iwamoto, Tamami Yoshitama, Tomoki Origuchi, Yukitaka Ueki, Nobutaka Eiraku, and Shuji Nagano
- Subjects
Male ,musculoskeletal diseases ,medicine.medical_specialty ,Injections, Subcutaneous ,Immunology ,Arthritis ,Disease ,Anti-Citrullinated Protein Antibodies ,Abatacept ,Arthritis, Rheumatoid ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Japan ,Internal medicine ,medicine ,Treatment persistence ,Immunology and Allergy ,Humans ,030212 general & internal medicine ,Prospective Studies ,Prospective cohort study ,Infusions, Intravenous ,Aged ,Ultrasonography ,030203 arthritis & rheumatology ,biology ,Dose-Response Relationship, Drug ,business.industry ,Anti–citrullinated protein antibody ,General Medicine ,medicine.disease ,Titer ,Treatment Outcome ,Rheumatoid arthritis ,Antirheumatic Agents ,biology.protein ,Female ,business ,Biomarkers ,medicine.drug ,Follow-Up Studies - Abstract
Objective: Successful rheumatoid arthritis (RA) outcome depends on treatment efficacy in the early stages of the disease and its sustainability. It is thus critical to identify factors predicting treatment persistence with biological agents, such as abatacept. We compared clinical profiles, including early changes in autoantibody titres at 3 months, between patients with RA demonstrating sustained persistence and those discontinuing abatacept treatment. Method: We prospectively enrolled 71 and 78 active RA patients treated with abatacept and tumour necrosis factor inhibitors (TNF-Is), respectively, who had previous disease-modifying anti-rheumatic drug) failure. Clinical characteristics were compared between non-continuation and continuation groups stratified according to abatacept or TNF-I persistence for at least 12 months from treatment initiation. Results: Significantly larger decreases in rheumatoid factor titre and anti-citrullinated protein autoantibody (ACPA) titre were observed in the continuation group of abatacept therapy at 3 months, and early reduction in ACPA titre remained a significant and independent predictor of sustained persistence with abatacept in multivariate analysis. In addition, we obtained the area under the receiver operator characteristics curve of 0.904 from a model including baseline ACPA titre and reduction of ACPA titre at 3 months. Sustained reduction of RA disease activity score at 12 months was significantly and independently associated with reduced ACPA titre at 3 months. Conclusions: Persistence with abatacept and sustained therapeutic response are associated with an early reduction in ACPA titre. Prediction of abatacept continuation and efficacy will facilitate the optimal design of therapy in the early stages of RA.
- Published
- 2019
- Full Text
- View/download PDF
44. Utility of a simplified ultrasonography scoring system among patients with rheumatoid arthritis
- Author
-
Toshimasa Shimizu, Ayuko Takatani, Naoki Iwamoto, Tomohiro Koga, Hirokazu Takaoka, Tamami Yoshitama, Yushiro Endo, Remi Sumiyoshi, Shimpei Morimoto, Tomoki Origuchi, Kunihiro Ichinose, Toshihiko Hidaka, Momoko Okamoto, Shin-ya Kawashiri, Akitomo Okada, Yoshifumi Tada, Atsushi Kawakami, Mami Tamai, Hiroaki Hamada, Arinobu Yojiro, Yukitaka Ueki, Keita Fujikawa, Naoki Matsuoka, Nobutaka Eiraku, Sosuke Tsuji, Shuji Nagano, Takashi Igawa, Hideki Nakamura, Tomomi Tsuru, Hideo Otsubo, and Ayako Nishino
- Subjects
Male ,rheumatoid arthritis ,musculoskeletal diseases ,medicine.medical_specialty ,Scoring system ,Observational Study ,Wrist ,Severity of Illness Index ,targeted synthetic DMARDs ,Arthritis, Rheumatoid ,Cohort Studies ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Tocilizumab ,Japan ,simplified US scoring system ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Aged ,business.industry ,Abatacept ,biological DMARDs ,ultrasonography ,General Medicine ,Middle Aged ,medicine.disease ,Rheumatology ,medicine.anatomical_structure ,chemistry ,030220 oncology & carcinogenesis ,Rheumatoid arthritis ,Cohort ,Female ,Tumor Necrosis Factor Inhibitors ,business ,Research Article ,medicine.drug ,Cohort study - Abstract
We aimed to evaluate the utility of a simplified ultrasonography (US) scoring system, which is desired in daily clinical practice, among patients with rheumatoid arthritis (RA) receiving biological/targeted synthetic disease-modifying antirheumatic drugs (DMARDs).A total of 289 Japanese patients with RA who were started on tumor necrosis factor inhibitors, abatacept, tocilizumab, or Janus kinase inhibitors between June 2013 and April 2019 at one of the 15 participating rheumatology centers were reviewed. We performed US assessment of articular synovia over 22 joints among bilateral wrist and finger joints, and the 22-joint (22j)-GS and 22-joint (22j)-PD scores were evaluated as an indicator of US activity using the sum of the GS and PD scores, respectively.The top 6 most affected joints included the bilateral wrist and second/third metacarpophalangeal joints. Therefore, 6-joint (6j)-GS and -PD scores were defined as the sum of the GS and PD scores from the 6 synovial sites over the aforementioned 6 joints, respectively. Although the 22j- or 6j-US scores were significantly correlated with DAS28-ESR or -CRP scores, the correlations were weak. Conversely, 6j-US scores were significantly and strongly correlated with 22j-US scores not only at baseline but also after therapy initiation.Using a multicenter cohort data, our results indicated that a simplified US scoring system could be adequately tolerated during any disease course among patients with RA receiving biological/targeted synthetic DMARDs., Medicine, 100(1), e23254; 2021
- Published
- 2021
45. Clinical features of elderly-onset Adult-onset Still's disease.
- Author
-
Akihito Maruyama, Ayako Kokuzawa, Yusuke Yamauchi, Yohei Kirino, Hideto Nagai, Yasushi Inoue, Toshiyuki Ota, Yutaka Chifu, Satomi Inokuchi, Syuichi Koarada, Akihide Ohta, Masahiro Iwamoto, and Yoshifumi Tada
- Subjects
STILL'S disease ,DISEASE remission ,OLDER people ,DISEASE complications ,PROGNOSIS - Abstract
Objectives: To clarify the characteristics of patients with elderly-onset Adult-onset Still's disease (AOSD). Methods: Patients were classified into elderly-onset (>60 years: 47 patients) and younger-onset (>60 years: 95 patients) groups according to their age at diagnosis of AOSD. Clinical features, treatments, and prognosis were compared between the elderly-onset and younger-onset groups. Results: In the elderly-onset group, compared with the younger-onset group, typical skin rashes were less frequent (21.3% vs 58.9%, respectively; p<.0001), whereas pleuritis (27.7% vs 7.4%, respectively; p=.0011) and disseminated intravascular coagulation (19.1% vs 2.1%, respectively; p=.0004) were more frequent, and serum ferritin levels were higher (median 12,700 ng/ml vs 2526 ng/ml, respectively; p<.0001). Overall survival and AOSD-related survival were reduced (p=.0006 and p=.0023, respectively) and drug-free remission was less frequent (p=.0035) in the elderly-onset group compared with the younger-onset group. Conclusions: Our results demonstrated that elderly-onset AOSD patients had several characteristics that differed from younger-onset AOSD patients, including less typical skin lesions, more AOSD-related complications, higher ferritin levels, and poorer prognoses. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Rosai-Dorfman Disease Presenting with Knee Arthralgia.
- Author
-
Akihito Maruyama, Arisa Ibi, Yuki Sato, and Yoshifumi Tada
- Published
- 2024
- Full Text
- View/download PDF
47. [Diagnostic (Classification) Criteria and Treatment Guidelines of Collagen-vascular Diseases: Hos to Use and Cautions on Applying Them for General Physicians. Topics: VI. Adult Still's Disease/Adult-onset Still's Disease]
- Author
-
Yoshifumi, Tada
- Subjects
Adult ,Adrenal Cortex Hormones ,Ferritins ,Humans ,Severity of Illness Index ,Still's Disease, Adult-Onset - Published
- 2018
48. Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease?
- Author
-
Yojiro Arinobu, Yoshifumi Tada, Syuichi Koarada, Yuri Sadanaga, Mariko Sakai, Rie Suematsu, Akihito Maruyama, Satomi Inokuchi, and Nobuyuki Ono
- Subjects
musculoskeletal diseases ,Adult ,Male ,medicine.medical_specialty ,Adult-onset Still's disease ,Immunology ,Sensitivity and Specificity ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,In patient ,030212 general & internal medicine ,Retrospective Studies ,030203 arthritis & rheumatology ,Receiver operating characteristic ,business.industry ,Macrophage Activation Syndrome ,fungi ,medicine.disease ,Predictive value ,Arthritis, Juvenile ,body regions ,Macrophage activation syndrome ,lipids (amino acids, peptides, and proteins) ,Female ,business ,Still's Disease, Adult-Onset ,hormones, hormone substitutes, and hormone antagonists ,Rheumatism ,Paediatric rheumatology - Abstract
The objectives of this study are to determine whether the 2016 European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organization classification criteria for macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (SJIA) can be used to identify MAS in patients with adult-onset Still's disease (AOSD). Using laboratory data from 76 AOSD patients with and without MAS, we analyzed the ability of the collective and individual constitutive elements of the 2016 MAS in SJIA criteria and additional laboratory measures to discriminate between AOSD patients with (n = 16) and without (n = 60) MAS. Cutoff values to determine the sensitivity, specificity, and predictive values were calculated from receiver operating characteristic curves, and modified classification criteria for MAS in AOSD were evaluated. The 2016 MAS in SJIA classification criteria had an overall sensitivity of 100%, specificity of 70.0%, positive predictive value of 47.1%, and negative predictive value of 100% to discriminate between AOSD patients with and without MAS based on laboratory data. Among the individual criteria, the sensitivity of triglycerides (46.7%) and the specificity of ferritin (15.0%) for MAS in AOSD were particularly low. The sensitivity and specificity for classifying MAS in AOSD patients were increased to 100 and 93%, respectively, by excluding triglycerides and changing the cutoff values for other criteria in the 2016 MAS in SJIA classification. The 2016 classification criteria for MAS in SJIA had higher sensitivity but lower specificity to identify MAS in AOSD patients compared with SJIA patients.
- Published
- 2018
49. Basic Knowledge of Rheumatoid Arthritis
- Author
-
Syuichi Koarada, Nobuyuki Ono, and Yoshifumi Tada
- Subjects
medicine.medical_specialty ,Basic knowledge ,business.industry ,Rheumatoid arthritis ,medicine ,Intensive care medicine ,medicine.disease ,business - Published
- 2018
50. Beneficial use of serum ferritin and heme oxygenase-1 as biomarkers in adult-onset Still's disease: A multicenter retrospective study
- Author
-
Kohei Nagasawa, Shuji Takei, Yasushi Kawaguchi, Seiji Minota, Hiroki Takahashi, Masahiro Iwamoto, Toshiyuki Ota, Akihide Ohta, Atsuhisa Ueda, Yohei Kirino, Hiroshi Tsukamoto, Takahiko Horiuchi, Hisae Ichida, Yoshifumi Tada, and Yoshiaki Ishigatsubo
- Subjects
Adult ,Male ,Disease ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Macrophage ,Medicine ,Humans ,030203 arthritis & rheumatology ,chemistry.chemical_classification ,biology ,business.industry ,Monocyte ,Retrospective cohort study ,Middle Aged ,Heme oxygenase ,Ferritin ,medicine.anatomical_structure ,Enzyme ,chemistry ,030220 oncology & carcinogenesis ,Immunology ,Ferritins ,biology.protein ,Biomarker (medicine) ,Female ,business ,Still's Disease, Adult-Onset ,Biomarkers ,Heme Oxygenase-1 - Abstract
Background: Heme oxygenase (HO)-1 is a heme-degrading enzyme highly expressed in monocyte/macrophage, serum levels of which may be promising biomarker for adult-onset Still’s disease (AOSD). We here report data on the use of serum ferritin and HO-1 levels in AOSD. Methods: Under the Hypercytokinemia Study Group collaboration, we collected sera from a total of 145 AOSD patients. Three independent experts judged whether the patients were definite AOSD depending on the clinical information. These 91 ‘definite AOSD’ patients were further divided into active, remission, and relapse groups. Forty-six cases of systemic vasculitis, sepsis, etc. were included as disease controls. Serum ferritin and HO-1 levels were measured using ELISA. Associations between clinical symptoms, serum ferritin, and HO-1 were explored. Multivariate regression analysis was performed to identify independent variables associated with definite AOSD diagnosis. Results: Serum ferritin and HO-1 levels were significantly higher in active and relapsed AOSD cases compared to disease controls, and were reduced by the treatment. Although a significant correlation was found between serum ferritin and HO-1 levels, a discrepancy was found in some cases such as iron-deficiency anemia. Receiver operating characteristic analysis identified optimal levels of serum ferritin (>819 ng/ml; sensitivity 76.1% and specificity 73.8%), and serum HO-1 (>30.2 ng/ml; sensitivity 84.8% and specificity 83.3%) that differentiated AOSD from controls. Interestingly, 88.9% of patients with AOSD who relapsed exceeded the cut-off value of serum HO-1 > 30.2 ng/ml, but only 50.0% exceeded serum ferritin >819 ng/ml (p = .013), suggesting that serum HO-1 levels may be a convenient indicator of AOSD disease status. Multivariate analysis identified neutrophilia, RF/ANA negativity, sore throat, and elevated serum HO-1 as independent variables associated with AOSD diagnosis. Conclusion: We confirmed that serum ferritin and HO-1 serve as highly specific and sensitive biomarkers for AOSD. A future prospective study with large sample size is necessary to determine whether these biomarkers could be included in Yamaguchi’s Criteria.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.